Live Breaking News & Updates on San Francisco Based Esker Therapeutics

Published: May 14, 2021
By Brandon May
Foresite Labs-incubated company Interline Therapeutics 
announced Thursday that it had raised $92 million in a financing round co-led by Foresite Capital and ARCH Venture Partners. The funding, which has officially launched the company, will be geared toward the development of therapies that correct dysfunctional protein communities to treat various diseases. 
The $92 million financing round is a combination of seed and Series A funding. The newly launched company says the proceeds will be funneled to facilitate the expansion of its research platform and advance a total of six preclinical therapeutic programs. 
Interline Therapeutics will specifically use genomics, proteomics, structural biology, and computational chemistry to “map and modulate protein communities” to construct a precision medicine platform focused on genomics, protein communities, and modulators of these communities. These three pillars ....

United States , San Francisco , Kinnate Biopharma , Warburg Pincus , June Lee , Vikram Bajaj , Zachary Sweeney , University Of California , Interline Therapeutic Co , Memorial Sloan Kettering Cancer Center , Interline Therapeutics , Foresite Capital , Memorial Sloan Kettering Cancer , Therapeutic Co Founder , Chief Executive Officer , Denali Therapeutics , Foresite Labs Incubated , San Francisco Based Esker Therapeutics , Foresite Labs , Orbimed Asia Partners , Orbimed Private , ஒன்றுபட்டது மாநிலங்களில் , சான் பிரான்சிஸ்கோ , வார்பர்க் பிங்கஸ் , ஜூன் லீ , விக்ரம் பஜாஜ் ,